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 Canyoudescribeyour
recentwork?
This is a personal account of the recent 
discovery of a new disease that had not 
been previously described (at least to my 
knowledge) [1]. There were many col-
leagues involved in this work, so this is 
simply one version of the discovery, as 
seen through my eyes. This project was 
quite multidisciplinary, drawing upon 
the expertise of clinical geneticists (Alan 
Rope, John Carey, John Opitz, Lynne 
Bird, Cathy Stevens and Sarah South), 
pathologists (Theodore Pysher and Steven 
Chin), bioinformaticians (Kai Wang, 
Evan Johnson, Chad Huff, Barry Moore, 
Jinchuan Xing and Mark Yandell) and 
biologists (Rune Evjenth, Johan Lillehaug 
and Thomas Arnesen), just to mention a 
few of the contributions.
My colleagues at the University of Utah 
(UT, USA) and Omicia, Inc. (CA, USA), 
a privately held company developing tools 
to interpret personal genome sequences, 
announced in Genome Research on 23 June 
2011 a new software tool called variant anno-
tation, analysis and search tool (VAAST), 
a probabilistic disease-causing mutation 
finder for individual human genomes [2]. A 
data interpretation bottleneck has limited 
the utility of personal genome informa-
tion for medical diagnosis and preventive 
care. VAAST is a new algorithm to assist 
in overcoming this bottleneck. VAAST 
is the product of a collaboration between 
Mark Yandell, PhD, associate professor of 
human genetics at the University of Utah 
School of Medicine, and colleagues, and the 
Omicia scientific team under the leadership 
of Martin Reese, PhD, the company’s CEO 
and Chief Scientific Officer. In their paper, 
Yandell and colleagues demonstrate that 
VAAST provides a highly accurate, statis-
tically robust means of rapidly searching 
personal genomes for genes with disease-
causing mutations. The authors demon-
strate that as few as three genomes from 
unrelated children, or those of the parents 
Interview
Personalaccountofthediscoveryofanewdiseaseusing
next-generationsequencing
Gholson J LyonspeakstoNatalieHarrison,CommissioningEditor
GholsonJLyon,MD,PhD,isaresearchscientistattheCenterforApplied
GenomicsatTheChildren’sHospitalofPhiladelphiaandattheUtah
FoundationforBiomedicalResearch(UFBR).Heisalsoanadjunctassistant
professorofPsychiatryatNewYorkUniversitySchoolofMedicine.Heis
aboard-certifiedchild,adolescentandadultpsychiatrist.Heearnedan
MPhilinGenetics,workingwithNobellaureateMartinEvansinCambridge,
UK, then received a PhD andMD through the Cornell/Rockefeller/
Sloan-KetteringTri-InstitutionalMD-PhDProgram.Hehaspublishedpeer-
reviewedpapersinbiochemistry,genetics,pharmacologyandmolecular
biology.Inadditiontohisresearchinterestinneuropsychiatricillnesses,
DrLyon is focusingon thediscoveryof rarepreviouslyundiscovered
Mendelian diseases. Recently Dr Lyon and a team of international
researchersusedanewdisease-variantfindingtool(variantannotation,
analysisandsearchtool[VAAST])toidentifythecauseofanextremely
rareX-linkedgeneticdisorderthatislethalininfancy.Thedisease-causing
mutationisintheNAA10 gene.Affectingonlymales,themutationcauses
anagedappearance, facial abnormalities, developmentaldelay and
cardiacarrhythmias,amongotherconditions.Theteamstudiedafamily
inUtahwithahistoryofseveralboyswiththesesymptomswhodiedin
infancy,andanalyzedDNAfromfiveboysinthefamily.Theyaretentatively
calling the disease Ogden syndrome, reflecting the family’s city of
residence.Thisstudyisoneofthefirsttimesinwhichnext-generation
sequencinghasbeenused tohelp identify and confirm thegenetic
etiology of a previously unknown and unreported disease. Dr Lyon
answerssomequestionsbelowregardingthiswork.
Gholson J Lyon
Utah Foundation for Biomedical Research, Salt Lake 
City, UT, USA  
and 
Center for Applied Genomics, Children’s Hospital of 
Philadelphia, PA, USA 
and 
NYU Child Study Center, NY, USA 
GholsonJLyon@gmail.com
Pharmacogenomics (2011) 12(11)1520 future science group
News & Views – Interview News & Views
and their two children, are sufficient to 
identify disease-causing mutations.
In a separate paper that we arranged for 
publication on the same day in the American 
Journal of Human Genetics, we reported the 
use of VAAST and other methods to i dentify 
the mutation responsible for a newly discov-
ered childhood disease. This new illness is 
characterized by aged appearance, craniofa-
cial abnormalities, cardiac arrhythmias and 
other symptoms. We used X-chromosome 
exon capture, next-generation sequencing 
and the VAAST tool to identify the dis-
ease-causing mutation in NAA10 that has 
resulted in this fatal disease in children of 
two unrelated families. We are now apply-
ing VAAST to many other unknown con-
ditions, including rare Mendelian disorders 
and other common disorders such as atten-
tion deficit hyperactivity disorder (ADHD) 
and autism.
 Whyisthisworkimportant
&whatisthesignificanceofit?
Harnessing the new generation of rapid, 
highly accurate gene-sequencing tech-
niques, our research team has identified the 
disease-causing mutation in a newly char-
acterized rare genetic disease by analyzing 
DNA from just a few individuals. The 
power and speed of the innovative bioinfor-
matics tool (VAAST) marks a step toward 
personalized genomics—discovering caus-
ative mutations in individual patients. Our 
research is proof-of-principle that VAAST 
can identify disease-causing mutations with 
greater accuracy, using DNA from far fewer 
individuals, more rapidly, than was previ-
ously possible. Although several of the exist-
ing software tools for ana lysis of personal 
genome sequences have been demonstrated 
to be sufficiently powered to identify muta-
tions underlying previously known disor-
ders, the current report is one of the first 
times a personal genome ana lysis tool has 
identified a previously unknown syndrome.
Sydney Brenner famously stated the fol-
lowing (paraphrase): “What I’m advocating 
is: go the other way. Let’s go from bedside 
to bench. We don’t have to look for a model 
organism anymore, because we are the 
model organisms”. I agree with Dr Brenner 
100%. Instead of compartmentalizing 
research and medicine, the two should be 
integrated so that physicians who are most 
familiar with human ‘phenotypes’ can 
inform the other arms of science. The advent 
of next-generation sequencing has made it 
i ncreasingly cheaper, faster and more feasible 
to sequence entire genomes or at least parts 
of the genome. This is leading to many new 
discoveries in genetic medicine, all of which 
is aided enormously by the initial sequenc-
ing of the human genome that was mostly 
completed approximately 10 years ago. The 
advent of exon capture and sequencing has 
made it possible to capture certain exons for 
sequencing and/or all of the known exons 
(referred to as the exome) for sequencing [3]. 
This enables the sequencing of unusual clin-
ical presentations which may have not been 
amenable to standard linkage ana lysis in the 
past, particularly if the clinical cases stem 
from just one family. Examples include the 
2010 publications on Miller syndrome [4,5], 
and similar studies aimed at identifying the 
unknown genetic defects responsible for 
some early childhood diseases [6].
One way to make headway in the genet-
ics of many complex disorders is to search 
for large pedigrees living in the same geo-
graphic location, where one can study the 
penetrance and segregation of variants in a 
similar environ mental background, free of 
population stratification concerns, particu-
larly given the possible penetrance of only 
approximately 40–60% for mutations in 
some disorders [7]. With the above in mind, 
2 years ago, I moved to the state of Utah, as 
I realized that studying genetic diseases in 
pedigrees will once again be quite fruitful 
going forward, with all the new technolo-
gies. While I started some of this work at 
the University of Utah, I have completed the 
work at the nonprofit Utah Foundation for 
Biomedical Research, which was founded in 
2010 to study many more pedigrees in Utah 
going forward [101].
While we were preparing and submitting 
the manuscript, a second research group at 
the National Human Genome Research 
Institute notified us that they too had iden-
tified the same NAA10 mutation in a sec-
ond family with three boys who had simi-
lar symptoms to those found in the Utah 
family. Further ana lysis demonstrated that 
the two families were unrelated – indicat-
ing that the disorder is a syndrome and not 
an isolated condition found only in one 
family. Although the detailed biological 
mechanisms remain to be investigated, the 
mutation in this disease alters an enzyme 
News & Views
www.futuremedicine.com 1521future science group
News & ViewsInterview – 
involved in a process called N-terminal 
acetylation, in which one end of a protein 
is modified by the addition of a chemical 
called an acetyl group. N-terminal acetyla-
tion occurs in approximately 80% of human 
proteins [8]; however, abnormalities in this 
specific p rotein modification have not 
p reviously been demonstrated to give rise 
to a human disorder. In this case, disrupting 
N-terminal acetylation results in symptoms 
ultimately causing death in infancy.
 Whatchallengesdid
youovercome?
To my knowledge, we were the first group to 
perform exon capture and sequencing in the 
core facility at the University of Utah, which 
was both challenging and exciting. We were 
aided enormously in this by Brian Dalley, 
who is an author on the paper. 
Collecting pedigrees in Utah is certainly 
made easier by the fact that the families tend 
to be larger and many people tend to remain 
in Utah. However, one challenge is that 
there is unfortunately no state-wide or even 
university-wide biobank, and each individ-
ual investigator must collect and store their 
own samples. In this instance, I drove to the 
family’s home in Ogden to meet the family 
and draw the blood on eight or so of the 
family members, and I obtained the rest of 
the DNA samples later on. Another chal-
lenge is that despite the fact that our medi-
cal system generates enormous amounts of 
clinical information on each patient, much 
of this information (rightfully so) is pro-
tected by privacy concerns. For one of the 
more recently deceased boys, a single-sided 
copy of the medical record is about one foot 
high! In the end, the easiest way for me to 
obtain the medical record was to get the 
family to obtain their own record, and the 
family graciously gave a copy of the record 
to me. In addition, several of the clinicians, 
including Alan Rope and Lynne Bird, sum-
marized much of the clinical phenotype for 
the paper, which was quite helpful.
Another challenge was that after we had 
completed the sequencing of five samples 
from the family, I decided that I wanted 
to prove further that the mutation was the 
cause of the disease. In order to do this, I 
wanted to test the DNA from the other 
three already deceased children in the fam-
ily. However, no one had collected their 
DNA for research. Luckily, at my request, 
Theodore Pysher, a pathologist and author 
on the paper, was able, with substantial 
persistence, to find two paraffin-embedded 
tissue blocks from the autopsies of two of 
the boys, saved in one case for approxi-
mately 30 years. Once again, owing to pri-
vacy concerns, the family had to sign writ-
ten authorization to release these blocks to 
me. Another author on the paper, Jeffrey 
Swensen, was able to isolate usable DNA 
from these blocks to check whether the 
mutation was present or not. It was pres-
ent, thus providing further proof that this 
is the causative mutation.
 Whatareyournextstepsgoing
tobe?
I am collaborating actively with Thomas 
Arnesen in Norway on trying to under-
stand how the defect in acetylation by the 
enzyme can lead to the pathophysiology of 
the disease, including the aged appearance, 
large hearts and eventual arrhythmias lead-
ing to death. I am also beginning to screen 
for drugs which might be able to restore 
activity of the enzyme, both to learn about 
how the enzyme functions and also perhaps 
to help any future boys born with this ill-
ness. However, it has taken over 20 years 
since the discovery of the genetic basis of 
cystic fibrosis for any drugs to be devel-
oped, and these drugs are still not US FDA 
approved to my knowledge [9]. So, it is a very 
long process from gene discovery to any 
drug development. More immediately, we 
have almost finished developing a Clinical 
Laboratory Improvement Amendments 
(CLIA)-certified laboratory test to screen 
for mutations in this gene, so we can tell 
the women in this and other families if 
they are carriers or not. Preimplantation 
genetic diagnosis and implantation could 
be used to allow female carriers to have 
normal children free of this disease, and it 
has been quite gratifying to discuss these 
possible options with the f amily in Utah.
I am also expanding my studies of pedi-
grees in Utah, and I work actively at the 
Utah Foundation for Biomedical Research 
(UFBR), which was founded last year by 
Reid Robison and Scott Duvall, partly to 
enable collection of pedigrees for research. 
We are planning to perform whole-genome 
sequencing of unusual cases going forward, 
as the costs of sequencing continue to 
drop dramatically.
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 Whatarethewiderimplications
oftheVAASTalgorithm?
In retrospect, the VAAST algorithm could 
have identified the causative mutation using 
data from just two individuals – an affected 
boy in one family and a mother (who was 
a carrier and not affected) in the unrelated 
family. This demonstrates that VAAST 
can potentially identify disease-causing 
mutations based on DNA from only two 
unrelated individuals, with the caveat that 
we had restricted our search space to the 
X-chromosome under the assumption that 
this was likely to be an X-linked disease. 
Based on this proof of principle, we hope 
that VAAST will accelerate the discovery 
of disease-causing mutations in both com-
mon, complex disorders such as ADHD and 
autism, and in rare Mendelian disorders. 
This will likely be true as more and more 
‘normal’ genomes are sequenced and added 
to the background genome file u tilized 
by VAAST.
 Whataretheregulatory
considerationsforthistype
ofwork?
This research had to be approved by an insti-
tutional review board as it involved human 
subjects. As I was employed at the time at 
the University of Utah, I was added to the 
Institutional review board protocol led by 
David Viskochil and approved for this use 
at the University of Utah. 
This was considered as ‘research’ during 
the discovery of the mutation. However, 
there is substantial debate in the medical 
genetics and ethics communities concern-
ing whether research results can be returned 
to participants or not. There really is no 
major or ‘correct’ consensus on this. Some 
people argue that all research results must 
be confirmed in a CLIA-certified labora-
tory prior to giving any such results back 
to patients. The Centers for Medicare and 
Medicaid Services (CMS) regulates all labo-
ratory testing – except research – performed 
on humans in the USA through the CLIA. 
In total, the CLIA covers approximately 
200,000 laboratory entities. The Division 
of Laboratory Services, within the Survey 
and Certification Group, under the Center 
for Medicaid and State Operations has the 
responsibility of implementing the CLIA 
Program. The objective of the CLIA pro-
gram is to ensure quality laboratory testing. 
Given this, we have had to develop a CLIA-
certified lab test at ARUP laboratories, in 
order to deliver any results back to the fam-
ily. Obviously, the women in the family who 
already had affected children knew that they 
were carriers of the mutation; however, there 
are women in the family that have not had 
children (yet) and they would like to know 
whether they are carriers of the mutation 
or not. We are working actively to get the 
test developed, so that we can return the 
results to these women in the family (along 
with making the test available to any other 
families, including Family 2 reported in our 
paper). To summarize the procedure that 
we have had to undergo; any clinical test at 
ARUP first has to go through a validation 
process by the R&D group; known samples 
are run through the test in a specific way, 
then the results are documented in a formal 
validation packet that is approved by man-
agement. All results are reviewed by medical 
directors. After the validation, accounting 
has to decide how the test will be billed, 
genetic counselors have to write the informa-
tion that will appear on the clinical reports 
and the test has to be formally transferred 
into the clinical laboratory (which involves 
putting paperwork in place, getting reagents 
in stock and training employees). In addi-
tion, the test usually has to be integrated 
into the computer system and ARUP test 
directory, although some of this can be 
bypassed if one requires that the test be 
specially ordered. Jeffrey Swensen and col-
leagues at ARUP have accomplished this for 
the specific mutation in NAA10, so we are 
now ready to begin performing the testing.
 Whatfuturetechnology
developmentwouldyouliketosee
thatcouldimprovethis
disease-variantfindingtool?
Mark Yandell’s group is working to incor-
porate into VAAST the ability to prioritize 
small deletions and duplications of DNA 
in the genome. Right now, VAAST mainly 
handles single nucleotide variants, which are 
single base pair changes in the 6 billion bp 
known to exist in a diploid human genome. 
It really is like finding a needle in a hay-
stack, and VAAST was developed to help 
find these needles.
I expect that the price of sequencing a 
whole genome will be US $1000 or less 
in the next 2–5 years. Once this occurs, 
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it will become cost effective to sequence 
entire genomes, rather than the targeted 
capture and sequencing that we performed 
for this study. I am particularly impressed 
by the whole genomes currently being 
sequenced and provided by the company, 
Complete Genomics (CA, USA), although 
the sequencing by Ion Torrent (USA) and 
Illumina (CA, USA) is also quite promising.
 Doyouhaveany
concludingremarks?
We are entering an exciting period in which 
we will discover and explain many idiopathic 
diseases, and I expect that we will soon dis-
cover many more mutations involved in 
autism, schizophrenia, Tourette’s syndrome, 
bipolar disorder, ADHD and obsessive-com-
pulsive disorder. It is too early to conclude 
what portion of neuropsychiatric disorders 
will end up being readily explained by single 
changes in the genome, and whether they 
will be point mutations, deletions, duplica-
tions or other forms of variation consistent 
with an oligogenic explanation. However, 
recent research has confirmed that 5% of 
autism can be explained by various large 
copy number variants [10,11], so it is likely 
that some additional portion of the heritabil-
ity will be explained by smaller mutations 
just not currently detected. However, prov-
ing causality will be the major issue, so hav-
ing access to research subjects and derived 
tissues will be critically important, hence 
the pressing need for clinician scientists to 
advance these efforts.
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